Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

Item

http://www.wikidata.org/entity/Q37132598

Q37132598

about

New molecularly targeted therapies for lung cancer A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.Vascular endothelial growth factor receptor-2 in breast cancer.Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study.Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528 The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.Angiogenesis inhibitors in the treatment of non-small cell lung cancer Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond New molecular targeted therapies for advanced non-small-cell lung cancer.Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509 Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer Bioanalysis in drug discovery and development.Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?Management of hypertension in angiogenesis inhibitor-treated patients.Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma.Angiogenesis in the treatment of non-small cell lung cancer.Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.Mode of action and clinical impact of VEGF signaling inhibitors.Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.Antivascular agents for non-small-cell lung cancer: current status and future directions.Novel VEGF signalling inhibitors: how helpful are biomarkers in their early development?Targeted agents in ovarian cancer.New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment.Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients.Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.

P2860

Q24680988-BAA1ADB2-C5AD-48D7-9CC1-13FAA08491A9 Q33399785-68F7614D-9D4F-4CC7-A736-C3F929718EED Q33415009-847DF116-1380-4713-9313-93E07345808D Q33429478-4D723A14-44D6-4D1E-83D5-0A3D566A668C Q33644407-D14F8527-49A3-4ABA-AD89-DFF3A6D7FB42 Q33684042-002A26D2-DFF0-4E04-82D6-2C72A960DEAC Q33912620-937D2CB8-0E32-41A2-9693-613FBD070595 Q33918044-B1BB6F47-CDC0-4DA2-A7D1-EEED451681E5 Q33972047-E1B60021-2A59-4BA4-A9CD-ECE6B6E21F0B Q34056295-BD1FB20F-0800-4B5C-9AF0-53CD66C3245D Q34322552-936EAA02-AC2A-4098-B9D9-FFEC9BE04799 Q34725749-F4F125CE-0413-41E0-8E15-52DF541D732D Q34854658-CA669653-65EB-40C7-93D8-6777944F3E5F Q35076198-8D4CB19F-22E8-4655-AC56-C5E5552073E2 Q35419004-A8E44154-1B40-48C1-A793-70DE5C131531 Q35659433-8CF335B0-D859-424E-9E2D-153DB049A2B1 Q35660763-69F6FE4E-2C83-4CC9-A100-5EDB6156ABCD Q35667806-D0440A82-165B-4521-91BF-DDA9E7C65D9F Q36270034-91A94993-75F1-48B5-82FE-6B9B282C06EE Q36274386-5A4B59BB-FD29-4272-AE09-DA958B4AB421 Q36287599-9A5E9B70-3AE4-4762-9997-14FF6BA9D6EA Q36337646-9EED1E0C-0B60-4309-AFC0-46088237EBFB Q36482542-A3B1DB36-732C-4C9F-B39D-7D25B6278ECB Q36671812-03B05F47-A924-4458-B9E2-A96735FAE9F4 Q36855961-2E92E8F7-2B75-4211-93C1-D2FE3515F2C2 Q36999705-A23733EB-544F-48D8-B777-8F5DB0A4399D Q37371312-584F4F16-1A0C-46B7-A510-F6458785F41B Q37385416-C0D73C55-3DED-43F3-942C-E8628DEA8266 Q37435385-B25AAA09-8B43-404B-8E50-1F13C0306D3C Q37474070-36258D7D-5756-413E-BA8F-CEE6C1409CFA Q37483987-B8F87EEC-75AA-4ED0-8875-F22FF33A6499 Q37486753-232FD19D-8BDD-4DA0-9C25-09F7C12E2D4D Q37624732-D0123589-F598-4920-98EE-E83FDD9D0416 Q37624735-B9DFE10A-61F4-4203-AF3B-E0B0CA5C35BB Q37795802-17D2544A-6DB7-4724-9ADF-F94D1D4040BD Q38014533-258C7EF3-800F-4E70-8662-C078681A7C32 Q38087392-76086FDB-78C7-40D9-8A5C-D07627F613EA Q38156262-BE4A2DAF-E2B7-49B1-BC77-D720FD4D4A3F Q38375556-9341ACD8-31C9-4385-81FC-ECFCDDE2993D Q38552109-59B07C67-9D2D-47D3-8FCB-76F31645FD9F

P2860

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

Item

http://www.wikidata.org/entity/Q37132598

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs